Drug intelligence / Profile preview

fac-[Re(bipy)(CO)3(MMB)]

Development stage: Preclinical
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

fac-[Re(bipy)(CO)3(MMB)] is a neutral rhenium(I) tricarbonyl complex that incorporates a 2,2'-bipyridyl (bipy) ligand and an S-donor ligand, MMB. This compound is part of a broader series of rhenium(I) tricarbonyl complexes currently under investigation for their potential applications in cell imaging, as well as for their anti-cancer and anti-microbial properties. While specific details for fac-[Re(bipy)(CO)3(MMB)] are not provided in the immediate context, related complexes within this series have demonstrated anti-proliferative activities in human breast cancer cell lines and have shown promise as organelle-specific probes, localizing predominantly in lysosomes and, with extended exposure, migrating to mitochondria.

Beyond the preview

Go deeper on fac-[Re(bipy)(CO)3(MMB)].

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fac-[Re(bipy)(CO)3(MMB)].

Explore the full profile